Arcturus Therapeutics Holdings Inc. (ARCT)
NASDAQ: ARCT · Real-Time Price · USD
11.58
-0.42 (-3.50%)
At close: Mar 28, 2025, 4:00 PM
11.61
+0.03 (0.27%)
After-hours: Mar 28, 2025, 7:56 PM EDT
ARCT Revenue
In the year 2024, Arcturus Therapeutics Holdings had annual revenue of $152.31M, down -8.69%. Arcturus Therapeutics Holdings had revenue of $22.77M in the quarter ending December 31, 2024, a decrease of -26.22%.
Revenue (ttm)
$152.31M
Revenue Growth
-8.69%
P/S Ratio
2.05
Revenue / Employee
$865,398
Employees
176
Market Cap
314.05M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 152.31M | -14.49M | -8.69% |
Dec 31, 2023 | 166.80M | -39.20M | -19.03% |
Dec 31, 2022 | 206.00M | 193.64M | 1,566.79% |
Dec 31, 2021 | 12.36M | 2.82M | 29.56% |
Dec 31, 2020 | 9.54M | -11.25M | -54.12% |
Dec 31, 2019 | Pro | Pro | Pro |
Dec 31, 2018 | Pro | Pro | Pro |
Dec 31, 2017 | Pro | Pro | Pro |
Dec 31, 2016 | Pro | Pro | Pro |
Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 400.28B |
Johnson & Johnson | 88.82B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
ARCT News
- 24 days ago - Arcturus Therapeutics Holdings Inc. (ARCT) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 24 days ago - Arcturus Therapeutics Announces Fourth Quarter and Fiscal Year 2024 Financial Update and Pipeline Progress - Business Wire
- 25 days ago - Arcturus Therapeutics to Present at Leerink's Global Healthcare Conference 2025 - Business Wire
- 4 weeks ago - Arcturus Therapeutics to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on March 6, 2025 - Business Wire
- 6 weeks ago - European Commission Approves CSL and Arcturus Therapeutics' KOSTAIVE®, the First Self-amplifying mRNA COVID-19 Vaccine - PRNewsWire
- 7 weeks ago - Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate - Business Wire
- 2 months ago - Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19 - Business Wire
- 2 months ago - Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference - Business Wire